Tenet Healthcare Stock Surges After Blockbuster Q2 Beat

Tenet Healthcare Corporation stocks have been trading up by 17.17 percent, driven mainly by strong earnings and upbeat guidance.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading THC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Q2 2026 adjusted EPS came in at $6.12 versus $4.26 consensus on $5.63B revenue, powered by strong same-store growth, tight cost control, and higher-acuity services.
Management lifted 2026 guidance to adjusted EPS of $20.30–$21.69 and revenue of $21.9B–$22.5B, with about $295M more EBITDA and $225M more free cash flow at the midpoint.
Share repurchase capacity increased by $2B after $1.04B bought back last quarter, leaving $2.13B available and targeting roughly a 6% reduction in share count at current prices.
The stock ripped more than 16–17% after the earnings release and guidance hike, strongly separating itself from a mostly flat healthcare tape.
Major banks including BofA, Barclays, Wells Fargo, UBS, and Guggenheim all stay positive on THC, with targets clustered roughly in the $231–$290 range.

Weekly Update Jul 20 – Jul 24, 2026: On Saturday, July 25, 2026 Tenet Healthcare Corporation stock [NYSE: THC] is trending up by 17.17%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Tenet Healthcare (THC) is operating as a top‑tier acute-care and ambulatory consolidator with sector‑leading profitability: EBIT margin 18.6%, EBITDA margin 22.8%, and consolidated net margin 7.9% on $21.3B revenue, all above typical hospital peers. Returns on equity (38–49%) and capital (10–25%) are exceptional, powered by strong asset turnover and mix shift to higher-acuity and ASC volumes. Leverage is elevated (total debt/equity 2.7x; LT debt/cap ~73%) but comfortably serviced (interest coverage 5.9x) and supported by $1.46B quarterly FCF, modest capex, and aggressive buybacks at a single‑digit P/E (~9x) and 0.7x sales.

The stock’s weekly tape shows a powerful breakout and follow‑through: from ~195 to a spike high near 233, closing at 233.2, confirming a vertical expansion in range with clear institutional demand. Intraday 5‑minute candles post‑earnings show repeated high‑volume buying above 220 and shallow pullbacks, indicating strong dip support rather than distribution. Dominant trend is firmly bullish. A key actionable level is $220: use it as primary support and stop zone for swing longs, with fresh entries on low‑volume pullbacks toward 225–228 targeting continuation above recent highs.

More Breaking News

Fundamentals, revisions, and positioning place Tenet ahead of both the Healthcare sector and Healthcare Providers & Services peers on growth, margins, and FCF conversion. Q2 results massively beat expectations, guidance for 2026 EPS and EBITDA moved materially above Street, and multiple banks raised targets into the $270–290 range as shares jumped >15%. Expanded $2B buyback plus $2.13B remaining capacity adds structural support. I see upside toward $275–285 over 12 months, with key support at $220 and interim resistance near $250.

Quick Financial Overview

Tenet Healthcare Corporation (THC) just printed the kind of quarter that resets expectations. Q2 2026 adjusted EPS of $6.12 not only smashed the $4.26 consensus, it also marked a sharp jump from last year’s $4.02. Revenue of $5.63B beat estimates and was backed by higher same-facility revenue and better hospital margins, not just accounting noise. For traders, that matters: strong price and volume in the business usually supports strong price and volume in the stock.

The guidance move is just as important. THC now sees 2026 adjusted EPS at $20.30–$21.69 and revenue at $21.9B–$22.5B, with about $295M more adjusted EBITDA and $225M more free cash flow at the midpoint. Key ratios back up this earnings power: EBIT margin sits around 18.6%, EBITDA margin roughly 22.8%, and return on equity is very high near 48.5%. The balance sheet is still leveraged with total debt-to-equity at 2.74, but interest coverage of 5.9 and free cash flow of about $1.46B for the recent quarter help support that load.

On valuation, THC trades around a 9.2 P/E and about 0.7 times sales, with price-to-free-cash-flow near 2.5, which is low for a name delivering this type of growth. The chart confirms that traders are re-rating the stock. Weekly data show a breakout from the high-$190s into the low-$230s, with a huge expansion in the range once earnings hit: a move from roughly $199 to a spike near $233–$235 in just days, and an intraday high around $246 on the post-earnings session before closing near $233. That kind of wide intraday bar after a gap up usually signals heavy participation and sets up a new trading range for the coming weeks.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!